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PROBLEM

METHODS

• GBS is part of the human microbiome but is also a leading
cause of infectious neonatal morbidity and mortality due to
vertical transmission during birth.
• Early Onset GBS (EOGBSD) disease onset 0-7 days
• Late Onset GBS (LOGBSD) disease onset 7-89 days
• Standard of care (SOC) GBS cultures obtained at 36-wks
• If present, receive Intrapartum antibiotic prophylaxis
• Intrapartum GBS cultures are not a standard of care.
• The current rate of EOGBSD in the US is 0.22/1000.
• The culture-based strategy has reduced EOGBS but not
eliminated GBS disease.
• Up to 80% of neonates with EOGBSD are born to those who
screened negative for GBS during SOC antenatal screening,1
this can be referred to as RESIDUAL GBS.

• Design This sub-study added an intrapartum exploratory arm
to an existing double-blind, randomized placebo-controlled
trial funded by the NIH.
•
The goal of the parent study was to demonstrate the
efficacy of an oral probiotic intervention to reduce GBS
colonization at 36 weeks gestation and
decrease the
need for IAP.
• Desired sample size was 25 participant/neonate dyads
• Measures: Intrapartum maternal GBS vaginal to rectal
cultures were collected by CNMs upon labor admission.
Neonatal oral and nasopharyngeal swabs were obtained
within the first two hours of life.
• Analysis Demographic and perinatal characteristics of substudy participants were analyzed using descriptive statistics.
• Intrapartum swabs were compared with SOC 36- week vaginal
to rectal GBS swabs
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OBJECTIVE
• To explore the outcomes of antepartum exposure to probiotic
or placebo on maternal and neonatal intrapartum Residual
GBS.
• Hypotheses: (a) more intrapartum participants in the
probiotics group will test negative for GBS on vaginal/rectal
swabs compared to those in the placebo group; and (b) fewer
neonates born of probiotic group participants will have GBS
on post-birth nasal-oral pharynx cultures compared to those
in the control group.
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• 30 intrapartum participants were enrolled
• 28 with complete data.
• There was one case of residual GBS ( probiotic group)
• There was a 13.3% rate of mismatch between 36- week SOC
cultures and intrapartum cultures.
• Logistic regression showed that 36-week SOC swabs
significantly predicted intrapartum GBS results (p=0.005).
• No GBS was recovered from neonatal oral and
nasopharyngeal swabs.

• Primary prevention strategies to reduce antepartum GBS
under investigation include probiotic use and vaccine
development.
• PROBIOTIC USE DURING PREGNANCY has been show to reduce the
probability of a GBS positive result by 44%3.

• The pathway of neonatal colonization to EOGBSD is not well
understood..
• The current strategy for GBS screening is the best available
but may result in both under and over treatment of GBS
during labor.
• Birthing people are exposed to large doses of IV antibiotics.
• Residual GBS remains a problem and continued research of
primary prevention for EOGBSD and LOGBSD deserve further
study, especially regarding probiotic use and vaccine
development.
• One barrier to these studies is the very large sample size that
will be needed to reduce EOGBSD.
• Probiotics have been found to reduce rates of antepartum
GBS colonization but did not reduce residual GBS in this substudy.
• Probiotics may be part of a future primary prevention
strategy to reduce antenatal GBS
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